Drug Profile
Aspacytarabine - BioSight
Alternative Names: Ara-C asparagine conjugate; Aspacytarabine-hydrochloride-BioSight; Asparagine ara-C conjugate; Asparagine cytarabine conjugate; Astarabine; BSR-236; BST 236; BST-236-HCl; Cytarabine asparagine conjugate; Cytarabine-prodrugLatest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator BioSight
- Developer BioSight; Groupe Francophone des Myelodysplasies
- Class Amino acids; Antineoplastics; Arabinonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Chronic myeloid leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from a phase II trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 16 Mar 2023 BioSight completes a phase II (ELPIS) trial in Acute myeloid leukaemia (First-line therapy) in USA and Israel (IV) (NCT03435848)
- 17 Aug 2022 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy, In adults, In elderly) in USA (IV) (NCT05503355)